Quick Answer
Nuvation Bio Inc. reported Cash And Cash Equivalents At Carrying Value of $164.09 million for the year ending 2025.
- Nuvation Bio Inc. showed an increase of +359.3% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
- This data is from Nuvation Bio Inc.'s annual report (Form 10-K), filed with the SEC on March 2, 2026.
- XBRL data for this metric is available from 2020 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2020: $3.4 thousand | Q3 2020: $1.34 million | Q1 2021: $638.90 million | Q2 2021: $449.53 million | Q3 2021: $344.63 million | Q1 2022: $106.21 million | Q2 2022: $102.32 million | Q3 2022: $138.69 million | Q1 2023: $30.07 million | Q2 2023: $50.07 million | Q3 2023: $24.40 million | Q1 2024: $34.51 million | Q2 2024: $34.29 million | Q3 2024: $30.04 million | Q1 2025: $47.98 million | Q2 2025: $247.97 million | Q3 2025: $98.90 million.
- Historical annual values: Fiscal year 2025: $164.09 million | Fiscal year 2024: $35.72 million | Fiscal year 2023: $42.65 million | Fiscal year 2022: $101.10 million | Fiscal year 2021: $132.42 million | Fiscal year 2020: $29.76 million | Fiscal year 2020: $0.00.
- Data sourced from SEC EDGAR public filings as of August 10, 2026.
Last verified: